Therapeutic advances over the last 20 years have led to an improved survival of patients with solid tumours, some being cured of their disease. However, an unwelcome consequence of this success has been an increase in the incidence of secondary malignancies. [1] [2] [3] Therapy-related myeloid neoplasms, including therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplasia, can occur in patients after therapy for both solid tumours and haematological malignancies. 3, 4 The cumulative risk of t-AML at 10 years after treatment for breast cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma and ovarian cancer, for example, has been estimated as 1.5, 3.8, 7.9 and 8.5%, respectively. 4 Commonly described risk factors for t-AML include the use of alkylating agents, topoisomerase II inhibitors and radiotherapy. Both the incidence and the latent period between primary therapy and therapy-related myelodysplasia or t-AML are dependent on the drug type administered, dose intensity and cumulative dose. 3, 5, 6 The risk of t-AML may also, in part, be due to inherited genetic factors. 2 These factors include polymorphisms within genes encoding detoxifying enzymes, such as members of the P450 protein family (CYP1A1), the quinone oxidoreductase enzyme (NQO1) and members of the glutathione S-transferase (GST) family, and polymorphisms within genes encoding DNA repair enzymes. 2 Detoxifying enzymes comprise two main groups. The first or phase I enzymes, such as Cytochrome P450s, yield highly reactive metabolites, which are subsequently detoxified and metabolized by the second or phase II enzymes, such as NQO1 and GSTs. 2, 7 DNA repair enzymes such as RAD51, XPD and XRCC3 are required to maintain genetic integrity and stability. Polymorphisms in the genes encoding either of these types of enzymes have been reported to increase susceptibility to a number of malignancies.
AML with t(8;16)(p11;p13);MOZ-CBP is a rare subtype of AML, the majority of cases of which are secondary to earlier therapy for a malignancy, therefore are t-AML. This type of AML is characterized by having monocytoid or myelomonocytic differentiation and erythrophagocytosis, and has an extremely poor prognosis. The t(8;16) translocation fuses the MOZ gene on chromosome 8p11 with CBP on 16p13. 8 The molecular consequence of this rearrangement is the generation of a novel MOZ-CBP fusion protein that inhibits RUNX1 regulated transcription, thereby leading to differentiation block. A reciprocal CBP-MOZ in-frame fusion has also been identified, although its role in leukaemogenesis is less well documented. Although the majority of cases of AML with t(8;16) (p11;p13);MOZ-CBP are secondary to therapy, it is not known whether there is some underlying genetic predisposition. We, therefore, studied three patients with t-AML with t(8;16);MOZ-CBP for polymorphisms in genes encoding detoxifying and DNA repair enzymes. All three patients had earlier received cytotoxic therapy for a primary malignancy, these being two cases of carcinoma of the breast and one case of small cell lung cancer (Table 1) .
Genomic DNA was prepared from all three patients. For patients 1 and 2, the remission sample was used. DNA polymorphism studies were undertaken for seven genes encoding detoxifying enzymes (three phase I and four phase II) and six DNA repair genes. These had all earlier been reported to be associated with an inherited predisposition to AML after therapy for a primary malignancy.
2 GSTM1 and GSTT1 gene deletion status was assessed by PCR amplification ( Table 2 ). All other genotypes were assessed using PCR amplification followed by digestion with a restriction enzyme ( Table 2) . In all cases, PCR and post-PCR digestion products were resolved on 3% agarose gels.
Genotypes reported to be associated with an increased risk of t-AML were detected in all three patients: six in case 1, four in case 2 and three in case 3 ( Figure 1 and Table 2 ). All three cases carried at least one variant allele at the GSTP1 Ile105Val locus. Cases 1 and 2 were heterozygous, whereas case 3 was homozygous Val/Val (Figure 1a ). t-AML has been reported to be associated with both the heterozygous and the homozygous Val/Val genotypes. Allan et al. 4 showed that individuals carrying at least one valine allele were twice as likely as homozygous Ile/Ile to develop t-AML after chemotherapy for a primary malignancy. Furthermore, this risk increased 4-fold in patients treated with GSTP1 substrates such as cyclophosphamide and carboplatin, drugs used in the management of all these patients. 
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Homozygous or heterozygous modification of GSTP1 at codon 105 affects both substrate-specific catalytic activity and thermal stability of the enzyme. 2 This reduces or eliminates the effectiveness of the enzyme leading to inadequate clearance of potentially genotoxic metabolites.
Polymorphisms in genes encoding DNA repair enzymes were detected in all three patients ( Table 2) . Case 1 had variant alleles of the XRCC3 Thr/Met locus (genotype Met/Met), XPD Lys751Gln (genotype Gln/Gln) and XRCC1 Arg399Gln (genotype Gln/Gln) (Figures 1c and d) . Case 2 was heterozygous at the RAD51 G-135C (Figure 1b) and XRCC3 Thr751Glu locus (Figure 1c) , and homozygous (Gln/Gln) at the XRCC1 Arg399Gln locus. Case 3 was homozygous (Gln/Gln) at XPD Lys751Gln (Figure 1d ) and heterozygous T/C at the hMSH2-6 exon 13 locus. Both the RAD51 and XRCC3 proteins are central to the repair of double strand breaks through homologous recombination. 2 Subtle changes of these enzymes due to coding region polymorphisms can usually be tolerated. However, certain alleles of RAD51 and XRCC3 can alter susceptibility to t-AML in patients treated with DNA-damaging chemotherapy. The presence of deleterious alleles is probably synergistic and not additive. For example, the Met allele of XRCC3 Thr241Met locus has little impact on risk (1.5-fold), and the RAD51 'C' allele at G-135C locus gives only a 2-fold increase in the risk of t-AML. 9 However, the presence of both alleles, as seen in case 2, increases the risk of developing t-AML by 8-fold. 9 The Lys751Gln polymorphism of the nucleotide excision repair enzyme XPD has also been associated with a modest 2-fold increased risk of developing chemotherapy induced t-AML. 10 Cases 1 and 3 were both homozygous for the Gln allele.
It is not known whether the polymorphisms in these patients were relevant in the pathogenesis of t-AML and, specifically, the t(8;16) translocation. However, all patients had polymorphisms, which would result in both the accumulation of drugs and their leukaemogenic metabolites and in inefficient DNA repair. The drug types most likely to be implicated are the topoisomerase II inhibitors (i.e. doxorubicin, mitoxantrone and etoposide). Topoisomerase II inhibitors have been linked with the formation of balanced translocations in t-AML, including t(8;21) and t(15;17), and translocations involving the MLL locus. It is of note that case 3 also carried a second t(1;19) translocation (Table 1) . Topoisomerase II binding sites have been identified at the genomic breakpoints of the fusion genes affected by such balanced translocations, indicating a direct link between treatment and genetic aberration. 6 Whether such binding sites are present at the genomic breakpoint of t(8;16) patients with t-AML is not known.
This report has identified up to eight 'high-risk' genotypes of detoxifying and DNA repair genes in three patients with t-AML with t(8;16)(p11;p13);MOZ-CBP. The most significant are likely to be GSTP1 Ile105Val, RAD51 G-135C substitution, XRCC3 Thr241Met and XPD Lys751Gln (reviewed in reference 2 ). It is possible, but unproven, that these genotypes contributed to the pathogenesis of the development of t-AML in these cases. Assessment of patients for these four genotypes, before intensive combination chemotherapy for solid tumours may, therefore, be Letters to the Editor worthy of consideration. The identification of potential 'high risk' alleles, such as GSTP1 Ile105Val and RAD51 G-135C, could allow individual tailoring of therapy for the primary tumour with a view to minimizing the risk of t-AML without compromising the potential cure of the primary malignancy. L-Asparaginase (ASNase; EC 3.5.1.1) is widely used in the treatment of acute lymphoblastic leukemia in combination with other anticancer drugs. The administration of L-asparaginase is followed by a rapid depletion of the L-asparagine concentration in plasma owing to its hydrolysis to L-aspartic acid and ammonia. Certain tumor cells, which lack or have a reduced level of L-asparagine synthetase, are dependent on their external supply of L-asparagine. Depletion of this supply by L-asparaginase suppresses the growth and development of the cells and induces their apoptosis.
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1 Serious side effects associated with the L-asparaginase therapy, including the development of antibodies against the bacterial proteins foreign to the human body, drug resistance and disturbance of the L-glutamine metabolism of various tissues owing to the L-glutaminase activity of the L-asparaginases, 2 have been related to the use of bacterial L-asparaginases. Owing to the problems with bacterial L-asparaginases, new agents that could induce apoptosis of L-asparagine-dependent tumor cells would be of major interest.
A lysosomal enzyme glycosylasparaginase (GA; aspartylglucosaminidase; EC 3.5.1.26) hydrolyzes the N-glycosidic carbohydrate-to-protein linkage region, aspartylglucosamine, to L-aspartic acid and l-amino-N-acetylglucosamine through a reaction mechanism similar to L-asparaginase. 3 Glycosylasparaginase is transported in active form into various non-neuronal cell types, including Epstein-Barr virus-transformed (EBV) glycosylasparaginase-deficient lymphoblasts, and it effectively corrects the metabolic defects in glycosylasparaginase-deficient cell lines 4 and mice. 5 The finding that human glycosylasparaginase also hydrolyzes L-asparagine to L-aspartic acid and ammonia-like bacterial L-asparaginases 6 without any L-glutaminase activity 3 led us to investigate its potential cytotoxic activity toward leukemia cells that are dependent on their external supply of L-asparagine.
We investigated the ability of human recombinant GA to deplete the intra-and extracellular Asn reservoirs in vitro using EBVtransformed glycosylasparaginase-deficient lymphoblasts from an
